These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35696053)

  • 1. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.
    Palandri C; Santini L; Argirò A; Margara F; Doste R; Bueno-Orovio A; Olivotto I; Coppini R
    Drugs; 2022 Jun; 82(8):889-912. PubMed ID: 35696053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol.
    Seo K; Yamamoto Y; Kirillova A; Kawana M; Yadav S; Huang Y; Wang Q; Lane KV; Pruitt BL; Perez MV; Bernstein D; Wu JC; Wheeler MT; Parikh VN; Ashley EA
    Circulation; 2023 Nov; 148(21):1691-1704. PubMed ID: 37850394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.
    Ammirati E; Contri R; Coppini R; Cecchi F; Frigerio M; Olivotto I
    Eur J Heart Fail; 2016 Sep; 18(9):1106-18. PubMed ID: 27109894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy.
    Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW
    Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Pharmacotherapy in Hypertrophic Cardiomyopathy.
    Andries G; Yandrapalli S; Naidu SS; Panza JA
    Cardiol Rev; 2018; 26(5):239-244. PubMed ID: 29746257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.
    Ferrantini C; Pioner JM; Mazzoni L; Gentile F; Tosi B; Rossi A; Belardinelli L; Tesi C; Palandri C; Matucci R; Cerbai E; Olivotto I; Poggesi C; Mugelli A; Coppini R
    Br J Pharmacol; 2018 Jul; 175(13):2635-2652. PubMed ID: 29579779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Pharmacotherapy for Hypertrophic Cardiomyopathy.
    Wong TC; Martinez M
    Cardiol Clin; 2019 Feb; 37(1):113-117. PubMed ID: 30447712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy].
    Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E
    Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.
    Gaballa A; Jadam S; Desai MY
    Expert Opin Pharmacother; 2024 May; 25(7):915-924. PubMed ID: 38813944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents.
    Hajj Ali A; Mehra N; Desai MY
    Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide.
    Willeford A; Silva Enciso J
    Pharmacotherapy; 2023 Dec; 43(12):1397-1404. PubMed ID: 37688422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy of hypertrophic cardiomyopathy].
    Hartmann A; Kaltenbach M; Hopf R
    Fortschr Med; 1992 Sep; 110(27):485-8. PubMed ID: 1358773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
    Tamargo J; Tamargo M; Caballero R
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
    Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
    Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial.
    Olivotto I; Hellawell JL; Farzaneh-Far R; Blair C; Coppini R; Myers J; Belardinelli L; Maron MS
    Circ Heart Fail; 2016 Mar; 9(3):e002764. PubMed ID: 26915375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.